Apoptose
Os inibidores da apoptose são compostos que previnem ou retardam o processo de morte celular programada, conhecido como apoptose. Esses inibidores são vitais no estudo dos mecanismos de sobrevivência celular e são usados para investigar doenças onde a apoptose é desregulada, como câncer, distúrbios neurodegenerativos e doenças autoimunes. Ao modular a apoptose, esses inibidores podem ajudar no desenvolvimento de terapias destinadas a controlar a morte celular. Na CymitQuimica, oferecemos uma ampla seleção de inibidores da apoptose de alta qualidade para apoiar sua pesquisa em biologia celular, oncologia e áreas relacionadas.
Subcategorias de "Apoptose"
- ASK(6 produtos)
- BCL(11 produtos)
- Caspase(125 produtos)
- FOXO1(3 produtos)
- IAP(66 produtos)
- Mdm2(12 produtos)
- PD-1/PD-L1(125 produtos)
- PDK(9 produtos)
- PERK(25 produtos)
- Serina/treonina quinase(15 produtos)
- Survivina(13 produtos)
- TNF(92 produtos)
- c-RET(51 produtos)
- p53(62 produtos)
Exibir 6 mais subcategorias
Foram encontrados 5598 produtos de "Apoptose"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
ZDLD13
CAS:<p>ZDLD13, a β-carboline, inhibits CDK4/CycD3, halts HCT116 tumor growth, and induces apoptosis with IC50=0.38μM.</p>Fórmula:C18H14N4OCor e Forma:SolidPeso molecular:302.33RIPK1-IN-11
CAS:<p>RIPK1-IN-11, an oral RIPK1 blocker, Kd 9.2 nM, IC50 67 nM, prevents necrosis and inflammation in cells.</p>Fórmula:C23H24N4O4SCor e Forma:SolidPeso molecular:452.53TNF-α-IN-1
CAS:<p>TNF-α-IN-1 is a TNF-α inhibitor.</p>Fórmula:C16H14ClN3O5Pureza:98.82%Cor e Forma:SolidPeso molecular:363.75DRAK2-IN-1
CAS:<p>Drak2-in-1: ATP-competitive DRAK2 inhibitor; IC50 = 3 nM, KI = 0.26 nM; affects DRAK1 (IC50 = 51 nM).</p>Fórmula:C21H20N4O3Cor e Forma:SolidPeso molecular:376.41LSD1-IN-14
CAS:<p>LSD1-IN-14: potent LSD1 inhibitor, IC50 0.89 μM; hinders A549/THP-1 cell growth, induces tumor cell apoptosis.</p>Fórmula:C21H24FN5Cor e Forma:SolidPeso molecular:365.45MM-102
CAS:<p>MM-102 (HMTase Inhibitor IX) is a potent inhibitor of WDR5/MLL interaction with IC50 of 2.4 nM and Ki of less than 1 nM in a WDR5 binding assay.Cost-effective and quality-assured.</p>Fórmula:C35H49F2N7O4Pureza:98.77% - 99.99%Cor e Forma:SolidPeso molecular:669.8BJE6-106
CAS:<p>BJE6-106 (B106) is a potent, selective PKCδ inhibitor (IC50: 0.05 μM) and targets selectivity over classical PKCα (IC50: 50 μM).</p>Fórmula:C26H23NO2Cor e Forma:SolidPeso molecular:381.47CSRM617
CAS:<p>CSRM617: selective ONECUT2 inhibitor, Kd 7.43 uM, binds OC2-HOX, induces apoptosis, tolerable in mouse prostate cancer model.</p>Fórmula:C10H13N3O5Pureza:98%Cor e Forma:SolidPeso molecular:255.23Selicrelumab
CAS:<p>Selicrelumab (RG-7876) is an antibody targeting CD40 with potential anti-tumor activity for the study of pancreatic cancer.</p>Pureza:98.7% (SDS-PAGE); 95.2% (SEC-HPLC) - 98.7% (SDS-PAGE); 95.2% (SEC-HPLC)Cor e Forma:LiquidNafamostat hydrochloride
CAS:<p>Nafamostat hydrochloride is a synthetic serine protease inhibitor and is an anticoagulant.</p>Fórmula:C19H19Cl2N5O2Pureza:98%Cor e Forma:SolidPeso molecular:420.29HSP90-IN-13
CAS:<p>HSP90-IN-13 (5k): potent HSP90 inhibitor, IC50 25.07 nM, targets EGFR/VEGFR-2/Topo-2, blocks MCF-7 G2/M cycle, induces apoptosis.</p>Fórmula:C26H21N5O3SCor e Forma:SolidPeso molecular:483.54hCAIX-IN-12
CAS:<p>hCAIX-IN-12: hCAIX inhibitor; IC50: 0.74 μM (CAIX), 10.78 μM (CAII); impedes cell growth, triggers apoptosis, boosts ROS; potential in CRC research.</p>Fórmula:C18H14N4O3S2Cor e Forma:SolidPeso molecular:398.46ICG-001
CAS:<p>ICG001 is a β-catenin/TCF-mediated transcription inhibitor that selectively blocks β-catenin/CBP interaction.Cost-effective and quality-assured.</p>Fórmula:C33H32N4O4Pureza:99.55% - 99.62%Cor e Forma:SolidPeso molecular:548.63Antitumor agent-45
CAS:<p>Antitumor agent-45 has an inhibitory effect on c-Met expression and is able to block A549 cells in the G0/G1 and G2/M phases and induce apoptosis.</p>Fórmula:C28H17BrFN5O3Cor e Forma:SolidPeso molecular:570.37NSC745885
CAS:<p>NSC745885 decreases EZH2, has selective cancer cell toxicity, and is studied for bladder and OSCC.</p>Fórmula:C14H6N2O2SPureza:98%Cor e Forma:SolidPeso molecular:266.27bpV(phen)
CAS:<p>bpV(phen) is a potent protein tyrosine phosphatase (PTP) and PTEN inhibitor (IC50s: 343 nM, 920 nM, and 38 nM for PTP-β, PTP-1B, and PTEN).</p>Fórmula:C12H8KN2O5VPureza:98%Cor e Forma:SolidPeso molecular:350.24RIPK3-IN-2
CAS:<p>RIPK3-IN-2 is a RIP3 inhibitor that can be used in studies of diseases caused by or associated with activated necrotic pathways.</p>Fórmula:C21H16ClN3O2S2Cor e Forma:SolidPeso molecular:441.95Anticancer agent 72
CAS:<p>Compound 8c inhibits K+ channel and induces apoptosis, showing promise as an anticancer agent.</p>Fórmula:C20H19N7O2Cor e Forma:SolidPeso molecular:389.41MIR002
CAS:<p>MIR002: an oral POLA1/HDAC11 inhibitor with antitumor effects, enhances p53/p21, causes G1/S arrest, and triggers apoptosis.</p>Fórmula:C27H29NO5Cor e Forma:SolidPeso molecular:447.52MI-192
CAS:<p>MI-192: Selective HDAC2/3 inhibitor, IC50=30/16 nM, induces apoptosis in myeloid leukemia, potential in leukemia/anti-stroke treatment.</p>Fórmula:C24H21N3O2Cor e Forma:SolidPeso molecular:383.44cRIPGBM
CAS:<p>cRIPGBM induces apoptosis in GBM CSCs by targeting RIPK2, with an EC50 of 68 nM in GBM-1 cells.</p>Fórmula:C26H20FN2O2Pureza:98%Cor e Forma:SolidPeso molecular:411.45Sparfosic Acid
CAS:<p>Sparfosic Acid (Acide sparfosique) is an aspartate carbamoyltransferase inhibitor with antitumor activity and can be used to study advanced renal cell carcinoma</p>Fórmula:C6H10NO8PPureza:98.89%Cor e Forma:SolidPeso molecular:255.12Estramustine phosphate
CAS:<p>Estramustine phosphate can be used to treat prostatic neoplasms; also has radiation protective properties.</p>Fórmula:C23H32Cl2NO6PCor e Forma:SolidPeso molecular:520.38DRI-C25441
CAS:<p>DRI-C25441 is a potent inhibitor of the CD40-CD40L interaction, exhibiting an IC50 value of 0.36 μM, and is capable of suppressing the immune response triggered</p>Fórmula:C31H21N3O6Cor e Forma:SolidPeso molecular:531.51DRI-C21041
CAS:<p>DRI-C21041 is a potent inhibitor of the CD40/CD40L interaction, demonstrating an inhibitory concentration 50 (IC50) value of 0.31 μM.</p>Fórmula:C30H21N3O7SCor e Forma:SolidPeso molecular:567.57Mcl1-IN-1
CAS:Mcl1-IN-1 is a myeloid cell factor 1 inhibitor (IC50=2.4 μM).Fórmula:C23H18ClN3O4Cor e Forma:SolidPeso molecular:435.86UCB-6876
CAS:<p>UCB-6876 inhibits TNF signaling, stabilizes trimer asymmetry, shows concentration response, and is selective for TNFR1.</p>Fórmula:C17H18N2OCor e Forma:SolidPeso molecular:266.34Pracinostat dihydrochloride
CAS:<p>Pracinostat dihydrochloride is a highly effective histone deacetylase (HDAC) inhibitor with IC₅₀ values ranging from 40 to 140 nM, utilized in cancer research. Additionally, it inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) hydrolase activity with an EC₅₀ of less than 10 nM.</p>Fórmula:C20H32Cl2N4O2Cor e Forma:SolidPeso molecular:431.40PI3Kα-IN-6
CAS:<p>PI3Kα-IN-6 (Compound 5b) is a PI3Kα inhibitor that exhibits anticancer effects without toxicity to normal cells.</p>Fórmula:C16H15IN2OSCor e Forma:SolidPeso molecular:410.27MMP-9-IN-4
CAS:<p>MMP-9-IN-4 inhibits MMP-9 (IC50=7.46nM) and AKT (IC50=8.82nM), induces apoptosis and is used in cancer research.</p>Fórmula:C28H19F3N4O6Cor e Forma:SolidPeso molecular:564.47Esuberaprost Sodium
CAS:<p>Famitinib (SHR1020), an oral drug, inhibits c-kit, VEGFR-2, and PDGFRβ (IC50: 2.3/4.7/6.6 nM) and triggers apoptosis in gastric cancer.</p>Fórmula:C23H27FN4O2Cor e Forma:SolidPeso molecular:410.48Vin-C01
CAS:<p>Vin-C01, a potent protector of pancreatic β-cells (EC50=0.22μM), aids in type 2 diabetes research by preventing STZ-induced β-cell apoptosis.</p>Fórmula:C20H24N2OCor e Forma:SolidPeso molecular:308.42Epofolate
CAS:<p>Epofolate: folate receptor-targeted antimitotic, delivers epothilone to cancer cells, inhibits mitosis, may halt tumor growth. Check clinical trials.</p>Fórmula:C67H92N16O22S3Cor e Forma:SolidPeso molecular:1569.74Apoptotic agent-2
CAS:<p>Apoptotic agent-2 reduces Bcl-2, boosts Bax & caspase-3, inducing apoptosis for cancer research.</p>Fórmula:C25H16ClN7SCor e Forma:SolidPeso molecular:481.96TJ08
CAS:<p>TJ08 has anticancer properties and can effectively induce G1/S phase blockade while promoting apoptosis in a variety of cancer cells.</p>Fórmula:C22H16FN3O4Pureza:99.89%Cor e Forma:SolidPeso molecular:405.38Tezacitabine
CAS:<p>Tezacitabine, a nucleoside analogue, inhibits ribonucleotide reductase, disrupts DNA replication, and induces apoptosis in tumor cells.</p>Fórmula:C10H12FN3O4Cor e Forma:SolidPeso molecular:257.22Tubulin/MMP-IN-2
CAS:<p>Tubulin/MMP-IN-2 blocks tubulin polymerization, MMP-2/-3/-9, induces apoptosis, aids cancer research, IC50: 24.95, 31.60, 22.37 µM.</p>Fórmula:C40H48NO11PCor e Forma:SolidPeso molecular:749.78EP12
CAS:<p>EP12, a c-Myc inhibitor and G4 stabilizer, induces apoptosis and DNA damage in multiple myeloma cells while obstructing P65/P50 nuclear translocation by</p>Fórmula:C26H22FN3O2Pureza:98%Cor e Forma:SolidPeso molecular:427.47Anticancer agent 164
CAS:<p>CML-IN-1, also known as compound 7 and compound 4, is a potent anticancer agent that demonstrates a strong induced-apoptosis effect in the human chronic myeloid</p>Fórmula:C21H23F3N8O2S2Pureza:98%Cor e Forma:SolidPeso molecular:540.58Antiproliferative agent-19
Antiproliferative agent-19 induces apoptosis and G2/M cell cycle arrest in lung cancer cells.Fórmula:C26H23NOCor e Forma:SolidPeso molecular:365.47Anticancer agent 47
CAS:<p>Compound 4j: potent anticancer agent; halts cell growth, induces apoptosis and G0/G1 arrest; significant in vivo tumor reduction.</p>Fórmula:C19H14N2O4SCor e Forma:SolidPeso molecular:366.39Ac-IETD-CHO
CAS:<p>Ac-IETD-CHO is a potent, reversible inhibitor of granzyme B and caspase 8, which also impedes Fas-mediated apoptosis, hemorrhagic conditions, and liver failure.</p>Fórmula:C21H34N4O10Pureza:98%Cor e Forma:SolidPeso molecular:502.52PBENZ-DBRMD
CAS:<p>PBENZ-DBRMD inhibits DIO3, has anti-growth effects, and aids apoptosis, showing promise for cancer research.</p>Fórmula:C11H5Br2NO4Cor e Forma:SolidPeso molecular:374.97Cinnabarinic acid
CAS:<p>mGlu4 receptor agonist</p>Fórmula:C14H8N2O6Pureza:98%Cor e Forma:SolidPeso molecular:300.22Antiproliferative agent-32
CAS:<p>Antiproliferative agent-32 (Compound 1c) impedes phosphorylation within the PI3K/Akt/mTOR signaling pathway, restrains proliferation of Huh7 and SK-Hep-1 cells</p>Fórmula:C19H15NO2Pureza:98%Cor e Forma:SolidPeso molecular:289.33Antitumor agent-115
CAS:<p>Antitumor agent-115 (SS-12) is a potent anti-tumor compound, exhibiting an IC50 range of 0.34 μM-24.14 μM against the 4T1 mouse breast cancer cell line.</p>Fórmula:C19H38ClNO2Pureza:98%Cor e Forma:SolidPeso molecular:347.96IDH1 Inhibitor 9
CAS:<p>IDH1 Inhibitor 9 (compound 11S) (2, 4, 8, 10 µM) induces apoptosis and causes cell cycle arrest in the S phase in a dose-dependent manner.</p>Fórmula:C26H30N4O3Cor e Forma:SolidPeso molecular:446.54SDZ 224-015
CAS:<p>SDZ 224-015 is an inhibitor of interleukin-1β (IL-1β) converting enzyme and caspase-1 with anti-COVID-19 and anti-inflammatory activity.</p>Fórmula:C30H35Cl2N3O9Pureza:95.49% - 95.49%Cor e Forma:SolidPeso molecular:652.52Metaproterenol
CAS:<p>Metaproterenol also has anti-inflammatory activity. Metaproterenol is a direct-acting sympathomimetic and a β2-adrenergic receptor (β2AR) agonist (IC50: 68 nM).</p>Fórmula:C11H17NO3Pureza:98%Cor e Forma:SolidPeso molecular:211.26Apoptosis inducer 8
CAS:<p>Apoptosis inducer 8 is a galectin-1 (gal-1)-mediated apoptosis inducer and a PET imaging agent that significantly reduces gal-1 protein levels and can be used</p>Fórmula:C29H22ClN5O2Cor e Forma:SolidPeso molecular:507.97CDK1/Cyc B-IN-1
CAS:<p>CDK1/Cyc B-IN-1: Potent CDK1/Cyc B inhibitor, IC50 97 nM, induces apoptosis, arrests G2/M cycle, halts cancer growth.</p>Fórmula:C14H12ClN3O2S2Cor e Forma:SolidPeso molecular:353.85CCT128930
CAS:<p>'CCT128930, potent Akt2 inhibitor (IC50=6 nM), 28x more selective over PKA.'</p>Fórmula:C18H20ClN5Pureza:99.07% - 99.18%Cor e Forma:SolidPeso molecular:341.84HJC0416
CAS:<p>HJC0416 is a potent orally bioavailable signal transducer and activator of transcription 3 inhibitor.</p>Fórmula:C18H17ClN2O4SPureza:98%Cor e Forma:SolidPeso molecular:392.86PDE5/HDAC-IN-1
CAS:<p>PDE5/HDAC-IN-1 is a potent inhibitor of phosphodiesterase 5 (PDE5) and HDAC, with IC50 values of 46.3 nM and 14.5 nM, respectively.</p>Fórmula:C27H29BrN4O4Cor e Forma:SolidPeso molecular:553.45RET-IN-12
CAS:<p>RET-IN-12 is a RET inhibitor capable of acting on RET(WT) (IC50: 0.3 nM) and RET(V804M) (IC50: 1 nM).</p>Fórmula:C30H30F3N5O4Cor e Forma:SolidPeso molecular:581.59BS-181
CAS:<p>BS-181 is a highly selective CDK7 inhibitor (IC50: 21 nM); >40-fold selective for CDK7 than CDK1/2/4/5/6/9.</p>Fórmula:C22H32N6Pureza:98%Cor e Forma:SolidPeso molecular:380.53VRT-043198
CAS:<p>VRT-043198, a VX-765 metabolite, is a potent ICE/caspase-1 inhibitor, crossing the blood-brain barrier with K i of 0.8/0.6 nM.</p>Fórmula:C22H29ClN4O6Cor e Forma:SolidPeso molecular:480.94Antitumor agent-44
CAS:<p>Antitumor agent-44 (Compound 5n) elicits potent antitumor effects by inducing disruption of mitochondrial homeostasis, cell cycle arrest, and apoptosis in human</p>Fórmula:C24H15N3O3Cor e Forma:SolidPeso molecular:393.39Antioxidant agent-5
CAS:<p>Antioxidant agent-5 (D-6) curbs oxLDL effects, ROS, NF-κB movement, apoptosis in VECs; boosts Nrf2/HO-1; protects endothelium.</p>Fórmula:C24H24N6OCor e Forma:SolidPeso molecular:412.49BR102375
CAS:<p>BR102375 is a non-TZD PPAR γ full agonist (EC50: 0.28 μM) for the treatment of type 2 diabetes.</p>Fórmula:C31H34N6O4Pureza:98%Cor e Forma:SolidPeso molecular:554.64CMLD012072
CAS:<p>CMLD012072 is a potent eukaryotic initiation factor 4A (eIF4A) inhibitor with potent anti-neoplastic activity. It can induce RNA clamping of eIF4A1 and eIF4A2.</p>Fórmula:C32H32N2O7Pureza:98%Cor e Forma:SolidPeso molecular:556.61AG6033
CAS:<p>AG6033, a novel CRBN modulator, degrades GSPT1/IKZF1 and inhibits various tumors.</p>Fórmula:C30H23N5O4Cor e Forma:SolidPeso molecular:517.53HDAC-IN-31
CAS:<p>HDAC-IN-31: Oral HDAC inhibitor; targets HDAC1, 2, 3; weak on HDAC8; potential in fighting lymphoma.</p>Fórmula:C25H24N4O2Cor e Forma:SolidPeso molecular:412.48RIPK1-IN-15
CAS:<p>RIPK1-IN-15 (Compound 2.5) is a potent RIPK1 inhibitor that has the potential in neurodegenerative, autoimmune, and inflammatory diseases research [1].</p>Fórmula:C19H19N3O2Cor e Forma:SolidPeso molecular:321.37Flonoltinib
CAS:<p>Flonoltinib (JAK2/FLT3-IN-1) is an orally active and efficient JAK2/FLT3 inhibitor with anti-cancer properties.</p>Fórmula:C25H34FN7OPureza:99.52%Cor e Forma:SolidPeso molecular:467.58Casein Kinase inhibitor A51
CAS:<p>Casein Kinase inhibitor A51 is a CK1α inhibitor with anticancer activity used in the study of breast and prostate cancer.</p>Fórmula:C18H25ClN6Pureza:99.88%Cor e Forma:SolidPeso molecular:360.88ABT-100
CAS:<p>ABT-100 is a potent, highly selective, and orally active farnesyl transferase inhibitor with broad-spectrum antitumor activity.</p>Fórmula:C27H19F3N4O3Pureza:98%Cor e Forma:SolidPeso molecular:504.46Sparfosic acid trisodium
CAS:<p>Sparfosic acid trisodium is a CAD (carbamoyl-phosphate synthetase 2) inhibitor and also an aspartate transcarbamoyl transferase inhibitor with antitumour</p>Fórmula:C6H9NNaO8PPureza:98%Cor e Forma:SolidPeso molecular:277.1NKP-1339
CAS:<p>NKP-1339 (IT-139) induces G2/M cell cycle arrest, blockage of DNA synthesis, and induction of apoptosis via the mitochondrial pathway.</p>Fórmula:C14H12Cl4N4NaRuPureza:98%Cor e Forma:SolidPeso molecular:502.14BMH-7
CAS:<p>BMH-7 (Histamine H4 receptor antagonist-2) is a p53 activator, demonstrating anti-cancer activity by activating the p53 pathway.</p>Fórmula:C20H21N5OPureza:99.71%Cor e Forma:SolidPeso molecular:347.41Prexasertib mesylate
CAS:<p>Prexasertib (LY2606368), a Chk1/2 inhibitor, enhances therapy in acute lymphoblastic leukemia, causing DNA damage and antitumor effects.</p>Fórmula:C19H23N7O5SPureza:98%Cor e Forma:SolidPeso molecular:461.49Verrucarin J
CAS:<p>Verrucarin J, a Myrothecium fungus metabolite, triggers apoptosis in some cancer cells and fights Candida, Mucor, and JUNV (IC50: 1.2 ng/mL).</p>Fórmula:C27H32O8Cor e Forma:SolidPeso molecular:484.54PAK4-IN-2
CAS:<p>PAK4-IN-2 inhibits PAK4 with IC50 2.7 nM, arrests MV4-11 cells at G0/G1, and induces apoptosis, promising for cancer research.</p>Fórmula:C18H21ClN6Cor e Forma:SolidPeso molecular:356.85PARP-1-IN-2
CAS:<p>PARP-1-IN-2 is a potent PARP1 inhibitor that crosses the blood-brain barrier (IC50: 149 nM).PARP-1-IN-2 showed significant antiproliferative activity against</p>Fórmula:C22H15Cl2N3O2Pureza:98.82%Cor e Forma:SolidPeso molecular:424.28CK2/ERK8-IN-1
CAS:<p>TMCB inhibits CK2 (Ki: 0.25 µM), ERK8 (IC50: 0.50 µM), PIM1, DYRK1A, HIPK2 (Ki: 8.65-15.25 µM), and induces apoptosis.</p>Fórmula:C11H9Br4N3O2Pureza:98.22%Cor e Forma:SolidPeso molecular:534.82GRI977143
CAS:<p>GRI977143: selective LPA2 agonist (EC50=3.3μM), blocks caspases 3/7/8/9, limits DNA fragmentation.</p>Fórmula:C22H17NO4SPureza:98.07%Cor e Forma:SolidPeso molecular:391.44PD180970
CAS:<p>PD180970 is an inhibitor of Bcr-Abl with IC50s of 5 nM, 0.8 nM and 50 nM for the autophosphorylation of p210Bcr-Abl, Src and Kit.</p>Fórmula:C21H15Cl2FN4OPureza:98.67%Cor e Forma:SolidPeso molecular:429.27MSN-50
CAS:<p>MSN-50, an inhibitor of Bax and Bak oligomerization, inhibits liposome permeabilization, prevents genotoxic cell death and promotes neuroprotection.</p>Fórmula:C36H38BrN3O6Cor e Forma:SolidPeso molecular:688.61N1,N11-Diethylnorspermine
CAS:<p>DENSPM: potent anticancer, spurs polyamine breakdown, triggers cytochrome c release and caspase 3, kills GBM via SSAT & H2O2.</p>Fórmula:C13H32N4Cor e Forma:SolidPeso molecular:244.42AP1867
CAS:<p>AP1867 is a synthetic FKBP12F36V-directed ligand.</p>Fórmula:C38H47NO11Cor e Forma:SolidPeso molecular:693.78LY5
CAS:<p>LY5 is an inhibitor of STAT3 that acts by inhibiting cell viability, cell migration, and angiogenesis in medulloblastoma cells.</p>Fórmula:C15H11N3O4SPureza:98%Cor e Forma:SolidPeso molecular:329.33W1131
CAS:<p>W1131 is a potent STAT3 inhibitor and ferroptosis trigger, reducing cancer progression and 5-FU resistance.</p>Fórmula:C23H19N5O4Cor e Forma:SolidPeso molecular:429.43LLL3
CAS:<p>LLL3 is a small molecule STAT3 inhibitor.</p>Fórmula:C16H10O4Cor e Forma:SolidPeso molecular:266.25IHMT-TRK-284
CAS:<p>IHMT-TRK-284: Oral type II TRK inhibitor; targets TRKA, TRKB, TRKC (IC50s: 10.5, 0.7, 2.6 nM); selective and anti-tumor effective.</p>Fórmula:C25H27N7OSCor e Forma:SolidPeso molecular:473.59PDK4-IN-1
CAS:<p>PDK4-IN-1 is an anthraquinone derivative and a potent and orally active inhibitor of pyruvate dehydrogenase kinase 4 (PDK4)(IC50 value of 84 nM).</p>Fórmula:C22H19N3O2Pureza:98%Cor e Forma:SolidPeso molecular:357.41PDMP (hydrochloride)
CAS:<p>PDMP, a glucosylceramide synthase inhibitor with 4 stereoisomers, acts at 0.8μM; D-threo enantiomer also blocks lactosylceramide synthesis.</p>Fórmula:C23H39ClN2O3Cor e Forma:SolidPeso molecular:427.03BRD4 Inhibitor-15
CAS:<p>BRD4 Inhibitor-15 targets BRD4 with 18 nM IC50, induces apoptosis in 22RV1 cells, and lowers c-Myc, aiding prostate cancer research.</p>Fórmula:C22H21N3O2Cor e Forma:SolidPeso molecular:359.42PDGFR-IN-1
CAS:<p>PDGFR-IN-1 is a platelet-derived growth factor receptor (PDGFR) inhibitor, strongly inhibiting PDGFRα and PDGFRβ, useful for studying solid tumors.</p>Fórmula:C25H30N8OPureza:99.13% - 99.49%Cor e Forma:SolidPeso molecular:458.56GW-3333
CAS:<p>GW-3333 inhibits matrix metalloproteinases and TNF-Converting Enzyme, showing potential as an antiarthritic therapy.</p>Fórmula:C22H36N4O4Pureza:98%Cor e Forma:SolidPeso molecular:420.55VMY-1-103
CAS:<p>VMY-1-103: a strong CDK inhibitor better than purvalanol B; halts prostate/breast cancer cell growth, induces apoptosis, may treat medulloblastoma.</p>Fórmula:C34H42ClN9O4SCor e Forma:SolidPeso molecular:708.27CRA-026440
CAS:<p>CRA-026440(PCI-34051) is a highly potent HDAC inhibitor with inhibitory effects on HDAC1, HDAC2, HDAC3, HDAC6, HDAC8 and HDAC10 with Ki values of 4,14,11,15,7</p>Fórmula:C23H24N4O4Pureza:96.42%Cor e Forma:SolidPeso molecular:420.46PI3K/AKT-IN-2
CAS:<p>PI3K/AKT-IN-2 inhibits PI3K/AKT, EMT, induces apoptosis, and blocks tubulin polymerization.</p>Fórmula:C32H27BrO10Cor e Forma:SolidPeso molecular:651.45Mcl1-IN-4
CAS:Mcl1-IN-4 is an inhibitor of Mcl1 ( IC50:0.2 μM).Fórmula:C28H26N2O5SPureza:98%Cor e Forma:SolidPeso molecular:502.58Didesmethylrocaglamide
CAS:<p>Didesmethylrocaglamide, a Rocaglamide derivative, is a potent eukaryotic initiation factor 4A (eIF4A) inhibitor that exhibits strong growth-inhibitory effects,</p>Fórmula:C27H27NO7Cor e Forma:SolidPeso molecular:477.51Semapimod
CAS:<p>Semapimod is an inhibitor of proinflammatory cytokine production, capable of suppressing TNF-α, IL-1β, and IL-6.</p>Fórmula:C34H52N18O2Cor e Forma:SolidPeso molecular:744.9DC-CPin711
CAS:<p>DC-CPin711: Potent, selective CBP bromodomain inhibitor, IC50=0.0626 μM; arrests G1 cell cycle, induces apoptosis.</p>Fórmula:C23H22N4O2Cor e Forma:SolidPeso molecular:386.45p-DDAP
CAS:<p>p-DDAP inhibits cell invasion and reduces MMP-9 activity and expression.</p>Fórmula:C18H31NOPureza:98%Cor e Forma:SolidPeso molecular:277.44HDAC6-IN-4
CAS:<p>HDAC6-IN-4 (C10), an oral, selective, potent HDAC6 inhibitor with low toxicity, IC50: 23 nM, promotes apoptosis and strong anti-tumor action.</p>Fórmula:C30H38N2O5Cor e Forma:SolidPeso molecular:506.63VEGFR-2/BRAF-IN-2
<p>VEGFR-2/BRAF-IN-2 inhibits VEGFR-2, BRAF V600E, BRAF WT (IC50: 0.111/0.089/0.071 µM); induces G1 arrest and apoptosis.</p>Fórmula:C26H21ClF3N5O3S2Cor e Forma:SolidPeso molecular:608.05Anti-inflammatory agent 15
CAS:<p>Compound 29, anti-inflammatory and antimycobacterial, halts Mtb H37Rv and M299 growth; MIC50 at 2.3 and 7.8 μM. Blocks iNOS, TNF-α, IL-1β.</p>Fórmula:C17H20N2SCor e Forma:SolidPeso molecular:284.42
